抗C5a治疗在早期/中期干性年龄相关性黄斑变性小鼠模型中的作用
研究在90周龄杂合补体因子H(Cfh+/-)小鼠中给予高脂高胆固醇饮食8周构建早期/中期干性年龄相关性黄斑变性(AMD)模型,并每周腹腔注射30 mg/kg抗C5a抗体(4C9,辉瑞)。抗C5a全身给药成功抑制单核吞噬细胞向脉络膜-RPE界面局部募集,但未改善该小鼠模型中的AMD样病理改变。
要点
- 老年Cfh+/-小鼠高脂饮食8周后出现RPE损伤、RPE下基底膜沉积、视功能减弱及免疫细胞向脉络膜募集。
- 每周腹腔注射30 mg/kg抗C5a抗体(4C9)抑制了单核吞噬细胞向脉络膜-RPE界面的局部募集。
- 抗C5a治疗未改善该小鼠模型中的AMD样病理改变,提示其他补体成分或机制可能驱动早期/中期AMD病理。
核心结论
- 靶向C5a的免疫治疗不足以阻断Cfh+/-∼HFC小鼠中观察到的AMD样病理改变的发生。
- 其他补体成分或分子/机制可能驱动「早期」和「中期」AMD病理。
研究设计与样本
- 研究使用90周龄杂合补体因子H(Cfh+/-)小鼠,给予高脂、高胆固醇饮食(Cfh+/-∼HFC)8周,并每周腹腔注射30 mg/kg抗C5a抗体(4C9,辉瑞)。
- 采用流式细胞术、视网膜色素上皮(RPE)铺片和视网膜电图对抗C5a治疗进行表征。
主要发现
- 老年Cfh+/-小鼠在高脂高胆固醇饮食8周后出现RPE损伤、RPE下基底膜沉积、视功能减弱以及免疫细胞向脉络膜募集,并伴有炎症和细胞外基质重塑基因表达。
- 同时给予抗C5a抗体全身给药成功抑制了单核吞噬细胞向脉络膜-RPE界面的局部募集,但未改善该小鼠模型中的AMD样病理改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A large body of evidence supports a central role for complement activation in the pathobiology of age-related macular degeneration (AMD), including plasma complement component 5a (C5a). Interestingly, C5a is a chemotactic agent for monocytes, a cell type also shown to contribute to AMD. However, the role monocytes play in the pathogenesis of "dry" AMD and the pharmacologic potential of targeting C5a to regulate these cells are unclear. We addressed these questions via C5a blockade in a unique model of early/intermediate dry AMD and large panel flow cytometry to immunophenotype monocytic involvement. METHODS: Heterozygous complement factor H (Cfh+/-) mice aged to 90 weeks were fed a high-fat, cholesterol-enriched diet (Cfh+/-∼HFC) for 8 weeks and were given weekly intraperitoneal injections of 30 mg/kg anti-C5a (4C9, Pfizer). Flow cytometry, retinal pigmented epithelium (RPE) flat mounts, and electroretinograms were used to characterize anti-C5a treatment. RESULTS: Aged Cfh+/- mice developed RPE damage, sub-RPE basal laminar deposits, and attenuation of visual function and immune cell recruitment to the choroid that was accompanied by expression of inflammatory and extracellular matrix remodeling genes following 8 weeks of HFC diet. Concomitant systemic administration of an anti-C5a antibody successfully inhibited local recruitment of mononuclear phagocytes to the choroid-RPE interface but did not ameliorate these AMD-like pathologies in this mouse model. CONCLUSIONS: These results show that immunotherapy targeting C5a is not sufficient to block the development of the AMD-like pathologies observed in Cfh+/-∼HFC mice and suggest that other complement components or molecules/mechanisms may be driving "early" and "intermediate" AMD pathologies.
引用
- Toomey CB, Landowski M, Klingeborn M, et al. Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018. PMID: 29392311. doi:10.1167/iovs.17-23134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。